Common Colds and Respiratory Viruses: Impact on Allergy and Asthma

Ioanna M. Velissariou, Paraskevi Xepapadaki, and Nikolaos G. Papadopoulos

Introduction

The association between common colds and acute wheezing episodes has been recognized for decades [1]. Indeed, wheezing associated with colds is the most common form of wheezing at all ages [2]. Although the nature of the debate has evolved over the years, many of the contradictory issues are still relevant, including whether episodic virus-induced wheezing in young children should be considered asthma. Furthermore, the debate continues over whether severe early viral infections have a causative role in the development of asthma, by immune modulation, airway damage, or both, or whether children who present with virus-induced wheezing have a pre-existing predisposition.

The clinical correlation of the common cold with asthma episodes is not recent. However, it is only in the last 10–15 years, with using sensitive methodologies for the detection of the most prevalent respiratory viruses, such as rhinoviruses and coronaviruses, we have been able to appreciate their importance [3, 4]. Furthermore, some of the most obvious changes in affluent societies, such as family structure, congregation, and hygiene, have implications for the epidemiology of infections, leading to speculation that infection-associated factors may be related to the asthma epidemic [5].

Using the polymerase chain reaction (PCR) and detailed analysis of epidemiological data, our understanding of the relationship between viral infections and asthma exacerbations has improved [6]. Nevertheless, there still are some apparently contradictory effects and many unexplored aspects to be addressed. The mechanisms by which respiratory viruses exacerbate asthma are under scrutiny. In addition, the possibility that some viral or intracellular bacterial infections may initiate asthma is still disputed. The subject has become more complicated since it was recognized that early exposure to microorganisms and/or different infections may actually protect against asthma, the so-called “hygiene hypothesis” [7].

I.M. Velissariou, P. Xepapadaki and N.G. Papadopoulos
Allergy Research Center, 2nd Pediatric Clinic, University of Athens, 41, Fidippidou Street, 11527, Goudi, Greece
Understanding the role of viral infections in the development of allergy and asthma may have implications on designing and selecting optimal therapeutic strategies, while indirectly affecting immunization programs, antibiotic use, and marketing of antiviral drugs, as well as the development of new approaches to therapy. This chapter addresses the interplay between viral infections, the immune system, and lung development, focusing on the possible role of respiratory viruses in the origin and exacerbations of asthma and allergy. Also presented are antiviral strategies for the prevention and treatment of virus-induced asthma exacerbations that have been investigated recently.

**Viral Infections and the Development of Allergy and Asthma**

To understand the potential implications of viral infections in the development of asthma, it has to be kept in mind that asthma has a complex natural history that includes different phenotypes, which may differ in their pathogenesis. It is well established that a majority of asthma cases start early in life. However, a significant proportion of children who wheeze at a young age, mostly after upper respiratory tract infections (URTIs), overcome their problem before school age. These subjects, characterized as ‘transient early wheezers’, have reduced airway function at birth; thus it is likely that their disease is at least partly mechanical rather than immunological in nature [8]. Other children commence wheezing early and continue to do so at least until adolescence. These persistent wheezers have an altered immune response with a rise in IgE levels during their first reported URTI, and no reduction in eosinophil numbers during the acute phase of the URTI, in contrast to transient wheezers [9].

The virus, most frequently associated with severe bronchiolitis in the first years of life, is the respiratory syncytial virus (RSV). RSV infection occurs in almost all children before their second birthday, and clinical presentations vary from subclinical to severe, life-threatening bronchiolitis [10]. Early studies have pointed out that children suffering from severe bronchiolitis have an increased risk of developing asthma in subsequent years [11]. Whether RSV bronchiolitis represents a marker of susceptibility to wheezing or it can per se divert the immune system or affect the lung and initiate asthma is not yet concluded. It is also possible that these pathways are not mutually exclusive: a pre-existing susceptibility may become clinically relevant once an exceptionally severe infection occurs (Fig. 1).

In 1971, Rooney and Williams [11] found that 56% of children hospitalized for bronchiolitis would continue to wheeze 2–7 years later, and this has been confirmed in several subsequent studies. However, it has been difficult to ascertain whether this is solely an association or whether causation is also involved, resulting from either direct lung damage or an RSV-mediated immunological deviation toward type-2 cytokine production [12]. Although pulmonary function is reduced many years later in children with a history of lower respiratory tract infection, it seems that this is a pre-existing feature of these children [8, 13].
When bronchial responsiveness was assessed, the results were conflicting; either no difference or an increase in bronchial reactivity several years after bronchiolitis has been reported [14]. Equally conflicting are the results relating to the potential effects of RSV in allergic sensitization. One group has shown that RSV bronchiolitis is an independent risk factor for the development of asthma and allergic sensitization at age 7 years, in fact a stronger risk factor than a family history of asthma [15]. In contrast, other studies have failed to establish such an effect [16, 17]. Differences in disease severity and age of evaluation may partly account for this discrepancy. It is conceivable that severe RSV disease may be required for the establishment of long-lasting effects. In another study, the correlation of RSV bronchiolitis with sensitization that was observed at the age of 6 was not present at age 9–10 years [18]. Importantly, RSV-related effects on wheezing and asthma decline with age, becoming nonsignificant by adolescence [17–19]. These findings should also be interpreted with caution: asthma symptoms may be undervalued in adolescence or may relapse later in life [20]; thus, prospective evaluation of the current cohorts is required to evaluate these possibilities. Most data relating to acute severe infections early in life and the increased risk of asthma implicate RSV, but most of the studies on which these conclusions are based have not adequately looked for other respiratory viruses, in particular rhinovirus (RV). Stein et al. [17] reported a fourfold increased risk of asthma later in life in children with RSV infections that were severe enough to lead to a pediatric consultation.

Fig. 1 Transient wheezing may be associated mostly with airway size at birth, resolving before school-age (1) severe RSV bronchiolitis in early life may be either the cause (2) or a marker of susceptibility (3) of asthma. These possibilities are not mutually exclusive, as it is possible that a viral attack may further affect immune programming in a susceptible host (4).
early in life. However, increased risks, —twofold to threefold, were observed with other respiratory viruses, suggesting that any single acute infection severe enough to lead to a pediatric consultation early in life is also a risk factor for asthma later in life. Although important as an observation, this lasting effect, possibly associated with human RV infections that were not virologically confirmed at the time, has not gained enough attention [17]. Nevertheless, it is supported by more recent findings showing that infection with human RV is more frequent during infancy than previously thought [21], can induce severe bronchiolitis [22], is associated with increased airway resistance [23], and is also more strongly associated with persistence of wheezing in the first 3 years of life [24].

A type-2/type-1 cytokine imbalance in favor of type-2 responses or with impaired type-1 responses in acute RSV bronchiolitis has been reported in several instances [25, 26]. These findings could be explained as either an inherent defect or a direct result of the RSV infection itself. A profound imbalance in infants with acute RSV bronchiolitis has been observed, with significantly reduced production of the type-1 cytokines interferon (IFN)-γ, interleukin (IL)-12, and IL-18 and increased production of IL-4 [27]. This imbalance was associated with impaired virus clearance, suggesting that it may be an important determinant of disease severity. In addition, because the imbalance was observed as early as the 1st or 2nd day after initiation of disease, the immune deviation was most probably already present in these infants before RSV infection; deviation of the immune response by the virus itself was unlikely to have occurred so early in the course of the illness, when virus-specific immunity was only beginning to develop [27].

From the above, it is obvious that no safe conclusion about whether RSV bronchiolitis may cause or is only associated with asthma in later life (through common causality) can be currently reached. Nevertheless, these two possibilities are not mutually exclusive. Children with a predisposition to asthma may be prone to develop severe RSV bronchiolitis; however, this infection may also further affect their immune responses and/or lung structure, leading to the development of asthma symptoms (Fig. 1) [28]. With the advent of effective RSV prevention modalities it is now possible to design randomized intervention studies. In these studies, confounding factors should be ruled out by randomization; thus they may offer more conclusive evidence. In one such study, modest differences in pulmonary function were observed between infants treated with ribavirin versus placebo-treated control infants, but the number of subjects was small [29]. Later intervention studies are awaited.

The Protective Effect of Respiratory Viruses on the Development of Allergy and Asthma

As respiratory viral infections are frequently the most apparent event in the presentation of asthma, either as a cause or as a marker, it seems contradictory that similar infections may protect against development of the disease. Nevertheless, the “hygiene hypothesis”, first suggested by Strachan [5], is a dominant theory used
to explain the increasing prevalence of allergies and asthma, based on our understanding of these diseases as dysregulations of the immune system. This subject has aroused much interest because of the findings of an effect of birth order and family size, as surrogate markers of infectious load, on the development of allergy [7, 29]. A protective role of infections also has been seen in developing countries, where an inverse relationship between evidence of respiratory infections and later development of atopy has been observed [30]. One possibility is that these findings could have resulted from a genetic bias in confined communities. However, this is unlikely, as there was a similarly reduced prevalence of atopic disease in East Germany compared with the genetically similar population of West Germany [31]. The East German children were assumed to have been exposed to more infections because of the much greater use of early childhood daycare facilities, which has been associated with less subsequent asthma [31].

There is a paradox, however, as several studies show that parental reports of lower respiratory illnesses are associated positively with later asthma [7]. A possible explanation is that daycare use and large family size are associated with an increased microbial load, which includes gastrointestinal viruses and other potentially protective microbes and is independent of the host response [7]. In contrast, parental reporting of symptoms reflects the host response. Children destined to have asthma have an impaired type-1 response to virus infections and are therefore at a risk of more frequent and severe symptoms, which are more likely to be reported.

In a prospective birth cohort study, children who had more than one respiratory illness confined to the upper respiratory tract during the first 3 years of life were at lower risk of having asthma symptoms at age 7 [31]. In contrast, when the infections were located in the lower airways, the risk for asthma increased significantly in a dose-dependent manner. Although the authors concluded that upper respiratory infections early in life may protect infants against the development of asthma, it is also possible that the development of upper or lower respiratory infectious disease is influenced to a considerable extent by the susceptibility of the host.

Another large birth cohort study found that personal and sibling viral infections (e.g., measles, mumps, rubella, hepatitis, chickenpox, herpes, mononucleosis) during the first year of life resulted in a small protective effect against the development of asthma (but not hay fever or eczema) later in childhood [32]. However, a strong protective birth order effect against all atopic diseases was present in that cohort. When respiratory tract infections as a whole were analyzed, a dose-dependent increased risk for asthma and hay fever was noted. Further, exposure to antibiotics was associated with an increased risk of developing allergic disease.

In another study, the detrimental effect of lower respiratory episodes during the first year of life in the expression of asthma at age 4 was confirmed, while no significant protective effect of upper respiratory infection was found in that setting [33]. An increased number of respiratory infections (e.g., measles, mumps, rubella, varicella) conferred increased risk for atopy in a Danish cohort, irrespective of the age of exposure: the presence of asthma was not assessed in that study [34].

It is probably too early to confirm a possible protective effect of respiratory viruses on the development of allergy and asthma. Prospective studies evaluating
exposure to microorganisms, pathogenic or not, as well as symptomatic infection, will be required to differentiate between the effect of these two factors, also taking into account possible confounders such as birth order and antibiotic use.

We recently proposed an alternative explanation for this apparent contradiction, using the term “incoordination” hypothesis [35]: the physiological rate of development and response of the human immune system may not match the rate of exposure to various stimuli as they currently appear in modern (especially “Westernized”) environments. Infectious agents, including viruses, are prominent, but not unique among these stimuli, as they are major determinants of immune maturation and their ecology is affected considerably by environmental changes, including, but not uniquely depending on, hygiene.

**Epidemiology of Viruses in Asthma Exacerbations**

Although the role of viruses in the induction of, or protection from allergy and asthma is still inconclusive, the evidence for the participation of these pathogens in asthma exacerbations is much stronger. The observation that asthma exacerbations often follow common colds is old and a daily experience of practicing physicians, especially pediatricians. Early reports documented that viral shedding decreased soon after the cold, before the patient referred to their physician or the hospital, indicating that early sampling was necessary for viral detection [36]. Furthermore, virus detection rates in these studies fluctuated considerably; this was attributed to difficulties in RV and corona virus identification. With the use of PCR-based detection for RV and prospective designs, the magnitude of the problem was revealed.

In a prospective study in the community, asthmatic children aged 9–11 years were followed up for 1 year and sampled as soon as they reported cold symptoms [37]. The percentage of asthma exacerbations following virologically confirmed colds was 80–85%. In children hospitalized with severe asthma exacerbations, the viral detection rate was 82% [38]. In adults, the proportion of virus-attributed asthma exacerbations was generally lower. However, it was possible that viral shedding was less or of a shorter duration in adults than in children. In one of the first community-based prospective studies using polymerase chain reaction (PCR) detection for rhinoviruses, virus detection rates were 44%, although cold symptoms preceded 70% of the episodes [39]. In another study (with a combined longitudinal and cross-sectional design) of inner-city asthmatic adults [40], virus detection was once again 44% in followed-up subjects and 50–55% in subjects presenting to the Emergency Department. In another study, virological confirmation was achieved in 60% of asthma exacerbations in adults [40]. Additional studies of similar designs have confirmed the high prevalence of viral infections in association with asthma exacerbations, with RV being the dominant pathogen [41–43].

The conclusion from the above is that respiratory viruses are the most common triggers of asthma attacks, and it is shown that such attacks can be severe, leading
to hospital admissions [44]. Peak in hospital admissions for asthma and virus isolation occurs, in most instances, immediately after school vacations. This pattern of a segregation-dependent disease is a characteristic of rhinovirus colds [45]. Similar seasonal variation has been partly observed in asthma mortality, especially among young children and the elderly, who are most susceptible to viral infections [46].

Another important point, on which all of these studies agree, is that RVs are the most prevalent agents, accounting for 50–60% of all detected viruses. This is thought to reflect the prevalence of these viruses in common colds, rather than any specific asthmagenic properties, because there are minor or no differences in symptoms produced by different viruses [37] or in the proportion of asthma episodes resulting from colds by any specific virus [36]. However, recent evidence from our laboratory suggests that RVs may have increased propensity toward inducing asthma in comparison to influenza viruses (NG Papadopoulos, unpublished data).

**Virus-Induced Changes in Airway Reactivity**

The above epidemiological data have raised considerable interest regarding the mechanisms of virus-induced asthma exacerbations, the understanding of which may suggest potential therapeutic targets. Airway hyperresponsiveness is one of the most prominent functional abnormalities in asthma that can be objectively assessed in human and animal models. An increase in airway responsiveness to histamine in normal subjects after URTIs, lasting as long as 7 weeks, was observed more than 20 years ago [47]. Although results have varied, probably because of differences in methodology, models, viral strains, and so on; increased airway reactivity has since been documented after RSV, influenza, parainfluenza, and adenovirus infections, mostly in animal models [48].

Because of the lack of appropriate animal models, human experimental infections have been used as a model for RV infection. Using this model, the increased airway responsiveness to histamine after RV infection in atopic asthmatic subjects was correlated with the severity of the experimental cold, which was paralleled by an increase in IL-8 in nasal lavage fluid [49]. In addition, when daily forced expiratory volume in 1 s (FEV₁) was monitored, a variable airway obstruction was observed [50]. When normal and atopic rhinitic subjects were compared, lower airway responsiveness was more affected in the allergic group [51]. However, in another study, experimental RV infection induced small changes in either upper or lower airway symptoms in normal and asthmatic subjects, with no effect on bronchial reactivity, leading the authors to suggest that RV infection by itself may not be sufficient to provoke clinical worsening of asthma [52]. Exposure to allergens during respiratory viral infection is the most obvious cofactor, because it is well known that rhinovirus experimental infection enhances the responses to inhaled allergens [53] and potentiates inflammation after segmental allergen bronchoprovocation [54]. Most surprisingly, Avila et al. [55], using the same human model in allergic rhinitis subjects, showed that pre-exposure of the nose to an allergen significantly delayed the onset of cold symptoms, reduced
the duration of the illness, and delayed the appearance of proinflammatory cytokines locally. An inverse correlation between nasal eosinophils at the time of inoculation and eventual cold symptoms was also observed, suggesting that an allergic response might protect from RV colds. Although this evidence seemed contradictory to most previous findings, it could prove helpful in several ways. First, it suggested that eosinophils could be involved in RV immunity [56]. Furthermore, it indicated that allergen exposure and viral infection did not have a simple additive effect, and timing or dosage may be important.

**Mechanisms of Virus-Induced Inflammation**

Several characteristics of virus-mediated pathology can also be seen in asthma. Among these, direct virus-mediated damage to lower airway epithelium is a characteristic of several viruses including influenza and RSV. Dead epithelial cells drop into the airway lumen, inducing or increasing airway obstruction. Although to a lesser extent, this is also the case for RV, which can infect the lower airways and induce cytotoxicity [57–59] (Fig. 2). Furthermore, RV infection induces the production of several cytokines and chemokines, including IL-6 and IL-8, regulated upon activation normal T cell expressed and secreted (RANTES), granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-16 [58, 59]. These studies strongly suggest that lower airway infection and local inflammation may represent the first step in the pathogenesis of an asthma episode, adding to and clarifying previous attempts to prove this notion [60, 61]. It is possible that the degree of inflammation, which is similar to other respiratory viruses [62], and not the degree of cytotoxicity, is more relevant in the induction of an exacerbation.

Epithelial damage and mediator production after viral infection are only some of the mechanisms that could initiate or sustain an asthma exacerbation. A dysfunction of the inhibitory M2 muscarinic receptor has been documented after viral infection, which could lead to increased reflex bronchoconstriction [63]. The role of tachykinins has also been suggested, partly explained by the reduction of neutral endopeptidase activity, which is the major metabolizing enzyme for substance P and neurokinin A.

![Fig. 2](image-url) In a simple model of epithelial wound healing, damaged epithelium \((t = 0)\) is suboptimally repopulated after RV-infection in comparison to sham-infected control. DAPI stained cells ((Published in *Respiratory Research* [57]))
Viruses in Allergy 149

Most of the above studies have been performed in animal models with cytotoxic viruses such as influenza, parainfluenza, and RSV. A neurally mediated effect does not seem to be a prominent feature of human experimental RV infections [65].

Most puzzling is the potential involvement of the immune response to respiratory viruses in asthma exacerbations. Although the asthmatic phenotype is paradigmatically related to type-2 lymphocyte responses, predominantly IL-4 and IL-5, viral infections induce strong type-1 responses with high levels of IFN-γ that would be expected to downregulate, rather than augment, “allergic” immune responses. Among respiratory viruses, RSV, influenza, and parainfluenza are more extensively studied in animal models. Sensitization of BALB/c mice to the virus attachment protein G of RSV, followed by live virus infection, leads to pulmonary eosinophilia and type-2 cytokine production. Although IFN-γ is still the dominant T-cell cytokine, a localized relative reduction of IFN-γ mRNA expression with a concomitant increase in IL-4 and IL-5 transcripts has been reported [66]. When Dermatophagoides farinae-sensitized mice were repeatedly infected with RSV, an increased production of type-2 cytokines was observed [67]. In the presence of IL-4, virus-specific CD8 T cells can switch to IL-5 production and induce airway eosinophilia [68]. Interestingly, IL-4 can also inhibit antiviral immunity, delaying both influenza [69] and RSV clearance.

RV-infected peripheral blood mononuclear cells from atopic asthmatic subjects produce significantly lower IFN-γ and IL-12 and significantly higher IL-10 and IL-4 than do cells from normal individuals [70]. Although IFN-γ remained the dominant T cell cytokine in this model, a shift toward a type-2 response may be involved in the induction of an asthma exacerbation, by mechanisms similar to the ones described above, for RSV in the mouse.

The recent discovery that airway epithelial cells are deficient in their capacity to generate INF-β when infected with RV raises the possibility that a defect in innate immunity might underlie exacerbations of asthma [71]. The normal response of the airway epithelium to virus infection is the induction of primary IFNs, such as IFN-β, through activation of the Toll-like receptor 3, which recognizes viral double-stranded RNA, leading to apoptosis that is able to effectively eliminate the infected cell and therefore limit viral replication and release. However, in asthmatic epithelial cells a major defect in this pathway leads to enhanced viral replication and virus-induced cell cytotoxicity [72]. Evidence that this pathway might be relevant to the persistence of asthma, as well as exacerbation, comes from the demonstration that in asthmatic patients RV can persist up to 6 weeks after infection [73] and in patients with severe asthma, RV is detectable in airway biopsy specimens between exacerbations [74].

Can Virus-Induced Wheeze Predict Later Asthma?

Most young children who wheeze initially present with episodes related to viral infections. Only a proportion of these children will continue to wheeze in later childhood and adulthood. For the first few years of life, these latter children remain
clinically indistinguishable from those with a transient wheeze. Therefore, it has been a long-standing aim of pediatricians to predict those who will have asthma later in life. In theory, anti-inflammatory remedies given early might modify the outcome [75], although recently it has been shown that early use of inhaled steroids for wheezing in preschool children had no effect on the natural history of asthma or wheeze later in childhood and did not prevent lung function decline or reduce airway reactivity [76]. From population studies, risk factors such as personal atopy or a family history of asthma could predict the relative risk of developing asthma with considerable accuracy, but for use in an individual, this approach is not sufficiently sensitive [77].

Because increased IgE levels and relative eosinophilia can be seen in infants that continue to have persistent wheeze, information obtained from a blood test during the initial episode could have some predictive potential [9]. However, this information has relatively low specificity and may not be ideal for day-to-day practice. It seems, therefore, that currently, a precise prediction of asthma persistence cannot be attempted from the initial virus-induced wheezing episodes.

Antiviral Strategies

Although possible, it is not certain whether a window of opportunity exists from the occurrence of a viral upper respiratory infection to the development of an acute asthma exacerbation, during which an antiviral strategy may be effective. In addition, we cannot predict whether immunization against one or more of the viruses involved will reduce virus-induced asthma exacerbations or it may simply shift the problem to different strains. To answer the above questions, reliable antiviral tools are required.

RVs represent the major causes of virus-induced asthma exacerbations; however, immunization options remain unsatisfactory, mainly due to the large number of

![Fig. 3](image)

Addition of salmeterol (S) either at $10^{-8}$ (A) or $10^{-9}$ (B) M to fluticasone propionate (F) at $10^{-9}$ M resulted in a significant reduction of RV-mediated VEGF production by epithelial cells, in a synergistic manner. $n = 4–6$, * $p < 0.05$, ** $p < 0.001$ (Adapted from Volonaki et al. [84])
different serotypes [29, 78]. A variety of antiviral agents against RV have been studied. Additional antiviral and anti-inflammatory strategies against common cold have been suggested with varying, but usually little, success [79]. Such strategies include the regularly used ascorbic acid, zinc, and Echinacea, which have little therapeutic value [78]. Macrolide antibiotics, batilomycin A1, erythromycin, and telithromycin have been shown to be effective as potential anti-inflammatory agents in vitro, but clinical proof is still insufficient [80, 81]. During the past few years antirhinoviral compounds such as pleconaril, acting by preventing the uncoating of picornaviruses [82], and the RV protease inhibitor rupintrivir [83], have shown promising results, but only in early-stage clinical trials.

Based on the above, strategies against virus-induced asthma and related exacerbations are, in principle, anti-inflammatory, following strategies against persistent asthma. Steroids combined with long-acting beta agonists may be effective in this setting: recent studies have shown that such combinations are synergistically effective in reducing RV-induced inflammation in vitro [84] (Fig. 3). Nevertheless, the extent to which these findings translate in clinical practice is still unspecified [85].

References

1. McIntosh K, Ellis EF, Hoffman LS, Lybass TG, Eller JJ, Fulqiniti VA (1973) The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children. J Pediatr 82(4): 578–590
2. Dodge RR, Burrows B (1980) The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 122(4): 567–575
3. Papadopoulos NG, Hunter J, Sanderson G, Meyer J, Johnston SL (1999) Rhinovirus identification by Bgl I digestion of picornavirus RT-PCR amplicons. J Virol Methods 80: 179–185
4. Xepapadaki P, Psarras S, Bossios A, Tsolia M, Gourgiotis D, Liapi-Adamidou G, Constantopoulos AG, Kafetzis D, Papadopoulos NG (2004) Human Metapneumovirus as a causative agent of acute bronchiolitis in infants. J Clin Virol 30: 267–270
5. Strachan DP (1989) Hay fever, hygiene, and household size. BMJ 299: 1259–1260
6. Johnston SL, Sanderson G, Pattemore PK, Smith S, Bardin PG, Bruce CB, Lambden PR, Tyrrell DA, Holgate ST (1993) Use of polymerase chain reaction for diagnosis of picornavirus infection in subjects with and without respiratory symptoms. J Clin Microbiol 31: 111–117
7. Mallia P, Johnston SL (2002) Respiratory viruses: do they protect from or induce asthma? Allergy 57: 1118–1129
8. Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM (1988) Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. New Engl J Med 319: 1112–1117
9. Martinez FD, Stern DA, Wright AL, Taussig LM, Halonen M (1998) Differential immune responses to acute lower respiratory illness in early life and subsequent development of persistent wheezing and asthma. J Allergy Clin Immunol 102: 915–920
10. Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140: 543–546
11. Rooney JC, Williams HE (1971) The relationship between proved viral bronchiolitis and subsequent wheezing. J Pediatr 79: 744–747
12. Smyth RL, Fletcher JN, Thomas HM, Hart CA, Openshaw PJM (1999) Respiratory syncytial virus and wheeze [letter]. Lancet 354: 1997–1998
13. Tager IB, Hanrahan JP, Tosteson TD, Castile RG, Brown RB, Weiss ST (1993) Lung function, pre- and post-natal smoke exposure, and wheezing in the first year of life. Am Rev Respir Dis 47: 811–817
14. Kattan M (1999) Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis. J Pediatr 135: 8–13
15. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B (2000) Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 161: 1501–1507
16. Toms GL, Quinn R, Robinson JW (1996) Undetectable IgE responses after respiratory syncytial virus infection. Arch Dis Child 74: 126–130
17. Stein RT, Sherrill D, Morgan WJ, Halberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD (1999) Respiratory syncytial virus bronchiolitis in early life and risk of wheeze and allergy by age 13 years. Lancet 354: 541–545
18. Noble V, Murray M, Webb MS, Alexander J, Swarbrick AS, Milner AD (1997) Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 76: 315–319
19. McConnockie KM, Roghmann KJ (1989) Wheezing at 8 and 13 years: changing importance of bronchiolitis and passive smoking. Pediatr Pulmonol 6: 138–146
20. Roorda RJ (1996) Prognostic factors for the outcome of childhood asthma in adolescence. Thorax 51(Suppl 1): S7–S12
21. van Benten I, Koopman L, Niesters B, Hop W, van Middelkoop B, de Waal L, van Drunen K, Osterhaus A, Neijens H, Fokkens W (2003) Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatr Allergy Immunol 14(5): 363–370
22. Papadopoulos NG, Moustaki M, Tsolia M, Bossios A, Astra E, Prezerakou A, Gourgiotis D, Cafetzi D (2002) Association of rhinovirus infection with increased disease severity in acute bronchiolitis. Am J Respir Crit Care Med 165(9): 1285–1289
23. Malmstrom K, Pitkaranta A, Carpen O, Pelkonen A, Malmberg LP, Turpeinen M, Kajosaari M, Sarna S, Lindahl H, Hahtela T, Makela MJ (2006) Human rhinovirus in bronchial epithelium of infants with recurrent respiratory symptoms. J Allergy Clin Immunol 118(3): 591–596
24. Lemanske RF Jr, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, Kirk CJ, Reisdorf E, Roberg KA, Anderson EL, Carlson-Dakes KT, Adler KJ, Gilbertson-White S, Pappas TE, Dasilva DF, Tisler CJ, Gern JE (2005) Rhinovirus illnesses during infancy predict subsequent childhood wheezing. J Allergy Clin Immunol 116(3): 571–577
25. Aberle JH, Aberle SW, Dworzak MN, Mandl CW, Rebhandl W, Vollnoher G, Kundi M, Popow-Kraupp T (1999) Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. Am J Respir Crit Care Med 160: 1263–1268
26. Openshaw PJ, Lemanske RF (1998) Respiratory viruses and asthma: can the effects be prevented? Eur Respir J (Suppl 27): 35–39
27. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO (2003) Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 168(6): 633–639
28. Rodriguez WJ, Arrobio J, Fink R, Kim HW, Milburn C (1999) Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis: Ribavirin Study Group. Arch Pediatr Adolesc Med 153: 469–474
29. Papadopoulos NG, Psarras S (2003) Rhinoviruses in the pathogenesis of asthma. Curr Allergy Asthma Rep 3: 137–145
30. Openshaw PJ, Hewitt C (2000) Protective and harmful effects of viral infections in childhood on wheezing disorders and asthma. Am J Respir Crit Care Med 162: 540–543
31. Illi S, von Mutius E, Lau S, Bergmann R, Niggemann B, Sommerfeld C, Wahn U: MAS Group (2001) Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. BMJ 322: 390–395
32. McKeever TM, Lewis SA, Smith C, Collins J, Heatlie H, Frischer M, Hubbard R (2002) Early exposure to infections and antibiotics and the incidence of allergic disease: a birth cohort...
study with the West Midlands General Practice Research Database. J Allergy Clin Immunol 109: 43–50
33. Celedon JC, Litonjua AA, Ryan L, Weiss ST, Gold DR (2002) Day care attendance, respiratory tract illnesses, wheezing, asthma, and total serum IgE level in early childhood. Arch Pediatr Adolesc Med 156: 241–245
34. Bager P, Westergaard T, Rostgaard K, Hjalgrim H, Melbye M (2002) Age at childhood infections and risk of atopy. Thorax 57: 379–382
35. Papadopoulos NG, Foteinos G (2007) Is allergy a result or a modifier of viral infections? An incoordination hypothesis. Allergy Clin Immunol Int (in press)
36. Pattemore PK, Johnston SL, Bardin PG (1992) Viruses as precipitants of asthma symptoms: I. Epidemiology. Clin Exp Allergy 22: 325–336
37. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O’Toole S, Myint SH, Tyrrell DA (1995) Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ 310: 1225–1228
38. Freymuth F, Vabret A, Brouard J, Toutain F, Verdon R, Petitjean J, Gouarin S, Duhamel JF, Guillois B (1999) Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children. J Clin Virol 13: 131–139
39. Nicholson KG, Kent J, Ireland DC (1993) Respiratory viruses and exacerbations of asthma in adults. BMJ 307: 982–986
40. Atmar RL, Guy E, Guntupalli KK, Zimmerman JL, Bandi VD, Baxter BD, Greenberg SB (1998) Respiratory tract viral infections in inner-city asthmatic adults. Arch Intern Med 158: 2453–2459
41. Ong BH, Gao Q, Phoon MC, Chow VT, Tan WC, Van Bever HP (2007) Identification of human metapneumovirus and Chlamydyphila pneumoniae in children with asthma and wheeze in Singapore. Singapore Med J 48(4): 291–293
42. Joao SM, Ferraz C, Pissarra S, Cardoso MJ (2007) Role of viruses and atypical bacteria in asthma exacerbations among children in Oporto (Portugal). Allergol Immunopathol (Madr) 35(1): 4–9
43. Jartti T, Lehtinen P, Vuorinen T, Osterback R, van der Hoogen B, Osterhaus AD, Ruuskanen O (2004) Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. Emerg Infect Dis 10(6): 1095–1101
44. Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, Cunningham A, Robinson BS, Myint SH, Ward ME, Tyrrell DA, Holgate ST (1996) The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 154: 654–660
45. Johnston NW, Johnston SL, Norman GR, Dai J, Sears MR (2006) The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 117(3): 557–562
46. Campbell MJ, Holgate ST, Johnston SL. (1997) Trends in asthma mortality: data on seasonality of deaths due to asthma were omitted from paper but editorial’s author did not know [letter]. BMJ 315: 1012
47. Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA (1976) Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 113: 131–139
48. Folkerts G, Busse WW, Nijkamp FP, Sorkness R, Gern JE (1998) Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med 157: 1708–1720
49. Grunberg K, Timmers M, Smits H, de Klerk EP, Dick EC, Spaan WJ, Hiemstra PS, Sterk PJ (1997) Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin Exp Allergy 27: 36–45
50. Grunberg K, Timmers MC, de Klerk EP, Dick EC, Sterk PJ (1999) Experimental rhinovirus 16 infection causes variable airway obstruction in subjects with atopic asthma. Am J Respir Crit Care Med 160: 1375–1380
51. Gern J, Calhoun W, Swenson C, Shen G, Busse WW (1997) Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects. Am J Respir Crit Care Med 155: 1872–1876
52. Fleming HE, Little FF, Schnurr D, Avila PC, Wong H, Liu J, Yagi S, Boushey HA (1999) Rhinovirus-16 colds in healthy and in asthmatic subjects: similar changes in upper and lower airways. Am J Respir Crit Care Med 160: 100–108
53. Lemanske RF Jr, Dick EC, Swenson CA, Vrtis RF, Busse WW (1989) Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 83: 1–10
54. Calhoun W, Dick E, Schwartz L, Busse W (1994) A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 94: 2200–2208
55. Avila PC, Abisheganaden JA, Wong H, Liu J, Yagi S, Schnurr D, Kishiyama JL, Boushey HA (2000) Effects of allergic inflammation of the nasal mucosa on the severity of rhinovirus 16 cold. J Allergy Clin Immunol 105: 923–932
56. Busse WW, Gern JE (2000) Do allergies protect against the effects of a rhinovirus cold? [editorial]. J Allergy Clin Immunol 105: 889–891
57. Bossios A, Psarras S, Gourgiotis D, Skevaki CL, Constantopoulos AG, Saxoni-Papageorgiou P, Papadopoulos NG (2005) Rhinovirus infection induces cytotoxicity and delays wound healing in bronchial epithelial cells. Respir Res 6: 114
58. Schroth MK, Grimm E, Frindt P, Galagan DM, Konno SI, Love R, Gern JE (1999) Rhinovirus replication causes RANTES production in primary bronchial epithelial cells. Am J Respir Cell Mol Biol 20: 1220–1228
59. Papadopoulos NG, Bates PJ, Bardin PG, Papi A, Leir SH, Fraenkel DJ, Meyer J, Lackie PM, Sanderson G, Holgate ST, Johnston SL (2000) Rhinoviruses infect the lower airways. J Infect Dis 181 : 1875–1884
60. Gern JE, Galagan DM, Jarjour NN, Dick EC, Busse WW (1997) Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med 155: 1159–1161
61. Subauste MC, Jacoby DB, Richards SM, Proud D (1995) Infection of a human respiratory epithelial cell line with rhinovirus: induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J Clin Invest 96: 549–557
62. Olszewska-Pazdrak B, Casola A, Saito T, Alam R, Crowe SE, Mei F, Oqra PL, Garofalo RP (1998) Cell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol 72: 4756–4764
63. Jacoby DB, Fryer AD (1999) Interaction of viral infections with muscarinic receptors. Clin Exp Allergy 29(Suppl 2): 59–64
64. Jacoby DB, Tamaoki J, Borson DB, Nadel JA (1988) Influenza infection causes airway hyperresponsiveness by decreasing enkephalinase. J Appl Physiol 64: 2653–2658
65. Grunberg K, Kuipers E, de Klerk E, de Gouw HW, Kroeis AE, Dick EC, Sterk PJ (1997) Effects of experimental rhinovirus 16 infection on airway hyperresponsiveness to bradykinin in asthmatic subjects in vivo. Am J Respir Crit Care Med 155: 833–838
66. Spender LC, Hussell T, Openshaw PJ (1998) Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. J Gen Virol 79: 1751–1758
67. Matsuse H, Behera AK, Kumar M, Rabb H, Lockey RF, Mohapatra SS (2000) Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. J Immunol 164: 6583–6592
68. Coyle AJ, Erard F, Bertrand C, Wullt S, Pincher H, Le Gros G (1995) Virus-specific CD8 cells can switch to interleukin 5 production and induce airway eosinophilia. J Exp Med 181: 1229–1233
69. Moran TM, Isobe H, Fernandez-Sesma A, Schulman JL (1996) Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J Virol 70: 5230–5235
70. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL (2002) A defective type 1 response to rhinovirus in atopic asthma. Thorax 57(4):328–332.
71. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, Davies DE (2005) Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 201: 937–947
72. Holgate ST (2006) Rhinoviruses in the pathogenesis of asthma: the bronchial epithelium as a major disease target. J Allergy Clin Immunol 118: 587–590
73. Kling S, Donninger H, Williams Z, Vermeulen J, Weinberg E, Latiff K, Ghidyal R, Bardin P (2005) Persistence of rhinovirus RNA after asthma exacerbation in children. Clin Exp Allergy 35: 672–678
74. Crisafi GM, Billmeyer EE, Sorkness RL (2006) The detection of rhinovirus RNA in severe asthma. Proc Am Thorac Soc 3: A15
75. Wilson NM (2003) Virus infections, wheeze and asthma. Paediatr Respir Rev 4(3): 184–192
76. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A, IFWIN study team (2006) Secondary prevention of asthma by the use of Inhaled Fluticasone Propionate in Wheezy Infants (IFWIN): double-blind, randomised, controlled study. Lancet 368(9537): 754–762
77. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD (2000) A clinical index to define risk of asthma in young children with recurrent wheeze. Am J Respir Crit Care Med 162(4 Pt1): 1403–1406
78. Papadopoulos NG, Papi A, Psarras S, Johnston SL (2004) Mechanisms of rhinovirus-induced asthma. Paediatr Respir Rev 5(3): 255–260
79. Yamaya M, Sasaki H (2003) Rhinovirus and asthma. Viral Immunol 16(2): 99–109
80. Suzuki T, Yamaya M, Sekizawa K, Hosoda M, Yamada N, Ishizuka S, Yoshino A, Yasuda H, Takahashi H, Nishimura H, Sasaki H (2002) Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med 165(8): 1113–1118
81. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB, TELICAST Investigators (2006) The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 354(15): 1589–1600
82. Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T, Collett MS, Pevear DC (2004) VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol 78(7): 3663–3674
83. Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyan P, Patrick AK, Smith GJ 3rd, Zalman LS (2003) Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 47(12): 3907–3916
84. Volonaki E, Psarras S, Xepapadaki P, Psomali D, Gourgiotis D, Papadopoulos NG (2006) Synergistic effects of fluticasone propionate and salmeterol on inhibiting rhinovirus-induced epithelial production of remodelling-associated growth factors. Clin Exp Allergy 36(10): 1268–1273
85. O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 172(2): 129–136